Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Dianthus Therapeutics, Inc. Common Stock

DNTH

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Last trade $87.13
Day change -$2.42 (-2.70%)
Day range $82.78 – $89.83
Volume 279,193
Market cap $5.04B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.04B
Price / earnings
—
Price / book
4.06×
Price / sales
1,855.34×
EV / sales
1,834.85×
EV / EBITDA
-21.14×

Profitability

Earnings per share
-$3.59
Return on assets
-15.84%
Return on equity
-16.28%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
30.02×
Quick ratio
30.02×
Cash ratio
1.95×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$175.85M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DNTH, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.21M$761K$463K$284K$396K$193K$1.16M$1.33M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$1.21M$761K$463K$284K$396K$193K$1.16M$1.33M
Selling, general and administrative$14.08M$13.56M$12.47M$9.93M$8.2M$8.87M$7.34M$6.83M
Research and development$45.6M$48.69M$34.53M$59.9M$32.49M$26.25M$27M$26.41M
Total operating expenses$59.68M$62.24M$47M$69.83M$40.68M$35.12M$34.34M$33.24M
Operating income-$58.47M-$61.48M-$46.53M-$69.54M-$40.29M-$34.93M-$33.18M-$31.92M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$46.64M-$50.22M-$40.83M-$64.43M-$36.77M-$31.63M-$29.51M-$28.44M
Income taxes$0$0$0$0$0$0$0$0
Net income-$46.64M-$50.22M-$40.83M-$64.43M-$36.77M-$31.63M-$29.51M-$28.44M
Net income attributable to common shareholders-$46.64M-$50.22M-$40.83M-$64.43M-$36.77M-$31.63M-$29.51M-$28.44M
EBITDA-$58.44M-$61.45M-$46.5M-$69.51M-$40.26M-$34.9M-$33.15M-$31.89M
Basic earnings per share-$0.81-$0.90-$0.85-$1.43-$0.97-$0.88-$0.82-$0.73
Diluted earnings per share-$0.81-$0.90-$0.85-$1.43-$0.97-$0.88-$0.82-$0.73

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?

Dianthus Therapeutics (DNTH) has gained 4.4% over the past four weeks and Wall Street analysts project a mean price target of $138.71, indicating a potential 61.2% upside from the current $86.03 price. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions with five upward revisions in the last 30 days and a 5.7% increase in consensus estimates. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.

GlobeNewswire Inc.

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics announced the grant of equity awards to three newly-hired, non-executive employees on November 2, 2026. The inducement grants consist of non-qualified stock options to purchase 26,000 shares of common stock with an exercise price of $82.25 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.

Zacks Investment Research

Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates

Regeneron reported Q3 2026 earnings of $20.07 per share, beating consensus estimates of $16.08 by 24.81%, with revenues of $5.12 billion exceeding expectations by 12.43%. The stock has underperformed the S&P 500 year-to-date, gaining 6.1% versus the market's 12.8%. Regeneron holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Dianthus Therapeutics is expected to report a quarterly loss of $1.00 per share with revenues of $0.7 million.

GlobeNewswire Inc.

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics granted equity awards to six newly-hired, non-executive employees on October 1, 2026. The inducement grants consist of non-qualified stock options to purchase 106,000 shares of common stock with an exercise price of $88.32 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.

GlobeNewswire Inc.

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Dianthus Therapeutics granted equity awards to six newly-hired non-executive employees on August 3, 2026, consisting of non-qualified stock options to purchase 87,000 shares at an exercise price of $106.02 per share with a 10-year term. The grants were approved by the Compensation Committee as material inducements for employment.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.